PSA Test Negligence in Ireland: When a Raised or Misread PSA Result Is Not Acted On
Reviewed for legal accuracy by Gary Matthews, Personal Injury & Medical Negligence Solicitor, Law Society of Ireland PC No. S8178 · Ormond Building, Dublin D07 · 01 9036408 ·
In short: PSA test negligence in Ireland happens when a raised PSA, or a suspicious prostate examination, is not acted on as the NCCP referral guideline requires, and a prostate cancer diagnosis is delayed as a result. Where that delay caused harm, it can support a personal injury claim.
The result is usually produced and read, but the clinical judgement that follows is wrong. The reading sits above the value for the man's age, or the examination is suspicious, yet no Rapid Access Prostate Clinic referral follows.1 It's the same pattern the Supreme Court compensated in Philp v Ryan, where a follow-up PSA was not acted on and prostate cancer was treated as prostatitis.5 If that happened to you or a family member, you can ask a solicitor to review your records.
On this page
This page is specific. It covers the PSA result itself becoming the point of failure. For the full picture of prostate cancer misdiagnosis claims, and for cases where a result was simply never reviewed at all rather than misjudged, see test results that were not followed up. This page sits within our wider guide to cancer misdiagnosis claims and to personal injury claims in Ireland.
How prostate cancer is missed when a PSA result is misread or not acted on
PSA test negligence usually happens after the test, not before it. A result comes back raised. Instead of acting on it, the doctor records it as nothing to worry about, puts it down to the man's age, or means to repeat it but never does. The opportunity for an earlier diagnosis is lost in that moment.
A PSA (prostate-specific antigen) test is a blood test, not a diagnosis on its own. The Irish Cancer Society describes it as a way of measuring a trend over time rather than a single yes-or-no answer. PSA can rise for benign reasons such as an enlarged prostate, infection or recent activity.4 That's exactly why the result has to be interpreted carefully, and why a careless interpretation can cause real harm.
Because this page focuses on the misjudged result, it differs from a claim where the result was genuinely lost or never seen. That scenario is covered in our guide to abnormal results that were not followed up. In our experience these claims cluster around three failure points after the blood is drawn. The first is the result filed as normal without the man being told. The second is a borderline result meant to be repeated, where no recall system brings the patient back. The third is a clearly elevated reading put down to a benign enlarged prostate without the further checks the guideline requires. A suspicious examination ignored because the PSA number looks acceptable falls into the same territory.
A linked failure is mistaking the cancer for something benign. Prostate cancer is regularly misread as prostatitis or a urinary tract infection, and the man is treated for the wrong condition while the cancer advances. That was the very pattern in Philp v Ryan, where prostate cancer was treated as prostatitis for eight months.5
Symptoms that should prompt a PSA test and examination
A man's symptoms can themselves be the trigger the doctor missed. Under the NCCP guideline, certain features should prompt a prostate assessment, meaning a PSA test and a digital rectal examination, and a referral where they point to cancer.1 The main ones are:
- Lower urinary tract symptoms such as needing to pass urine at night, frequency, urgency, hesitancy or a weak flow.
- Blood in the urine or semen.
- Erectile dysfunction with urinary symptoms.
- Features suggesting advanced disease, such as new bone or back pain at rest, unexplained weight loss, or symptoms of spinal cord compression.12
Where a man presented with these and no PSA test, examination or referral followed, the failure to investigate can itself be the breach. The guideline also lowered the age at which an asymptomatic man qualifies for referral from 50 to 40, so a younger man with a persistent raised PSA should not be dismissed on age alone.12
Why this is a recognised failure point: the NCCP Rapid Access Prostate Clinic pathway
The Irish route for a man with symptoms or an abnormal result runs through the National Cancer Control Programme (NCCP) and its Rapid Access Prostate Clinics. A failure to use that route correctly is where many claims begin. Ireland doesn't run a national screening programme for prostate cancer, so there's no automatic call-up the way there is for BreastCheck or CervicalCheck.4
These clinics were set up in 2009 and now operate in eight designated cancer centres: Beaumont, the Mater and St James's in Dublin, St Vincent's, Cork University Hospital, University Hospital Galway, University Hospital Limerick and University Hospital Waterford.1 A GP refers electronically through Healthlink, and the NCCP sets a target of seeing the patient within 20 working days.
This is the Irish framework that matters. A great deal of online material imports the UK "two-week-wait" and NICE referral rules, which don't apply here. Irish breach analysis is measured against the NCCP guideline, not a foreign one. The pathway can fail on the clinic side as well as the GP side. In late 2025 the HSE had to apologise after new referrals to the Galway Rapid Access Prostate Clinic, the busiest in the country, were suspended for several weeks without GPs being told. The 20-working-day target was missed for that period.6
Why Irish guidance differs from UK pages. Much of what you will read online, and some answers from AI tools, is written for England and is wrong for Ireland in four ways that matter to a claim. If you have been told otherwise, check whether the source is referring to Irish or UK law:
- The threshold is age-related under the NCCP guideline, not a flat PSA of 4.0 that some UK pages quote.1
- Irish referral turns on the NCCP criteria (a persistent raised age-specific PSA, or a suspicious examination), not the NICE "two-week-wait" pathway.
- The time limit in Ireland is two years from your date of knowledge, not the three years that applies in England.
- Loss of chance remains arguable in Ireland under Philp v Ryan, whereas in England Gregg v Scott largely closed that door.5
Two cluster guides cover the surrounding questions. Where the issue is who carries the legal responsibility for a referral that should have happened, our guide to GP versus hospital delay explains how that's apportioned. The underlying duty to refer is set out in our guide to failure to refer for urgent investigation.
Age-related PSA thresholds and the repeat rule
What counts as a raised PSA depends on a man's age, and applying a single flat "normal" figure to every man is a common source of error. PSA naturally rises as men get older, so a flat figure is misleading. The NCCP National Prostate Cancer GP Referral Guideline sets age-related reference values. A reading at or above the value for the age band, with a normal examination, points towards referral rather than reassurance.1
| Age group | Normal age-related PSA | Treated as raised at |
|---|---|---|
| Under 50 | Less than 2 µg/L | 2 µg/L or above |
| 50 to 59 | Less than 3 µg/L | 3 µg/L or above |
| 60 to 69 | Less than 4 µg/L | 4 µg/L or above |
| 70 and over | Less than 5 µg/L | 5 µg/L or above |
Two further rules from the same guideline matter for negligence. First, where a PSA is raised but the examination is normal, the test should be repeated in 6 to 12 weeks in the same laboratory. A reading that stays raised should then be referred.1 Second, the test should never be read in isolation from a digital rectal examination. The guideline is explicit that a suspicious examination warrants urgent referral to a urologist regardless of the PSA value.1 Irish Rapid Access Prostate Clinic data, published in the British Journal of General Practice, supports this. An abnormal examination carries a real risk of cancer even when the PSA reads normal.13 That's why a "normal" PSA doesn't always close the door on a claim, a point men are often surprised by, and one we return to in the questions below.
One technical trap is worth naming. Men taking finasteride or dutasteride for an enlarged prostate have their PSA suppressed, roughly halved, by the medication. The guideline notes that any rise on these drugs may indicate cancer and should prompt referral even if the absolute number still looks low.1 A doctor who reads the raw figure without accounting for the medication can be lulled into false reassurance.
A rising PSA that stays "in range"
A separate question is the rising trend. A man's PSA can climb year on year while still sitting under his age threshold, and the trend itself can be a warning sign. This is genuinely debated in the medicine. The rate of change, sometimes called PSA velocity, is not a settled test. A large US study found it did not reliably improve cancer detection, and no fixed velocity figure forms part of the Irish referral guideline.11 Irish referral still turns on the absolute age-related value and the repeat rule above, not on a velocity number. The practical point for a claim is narrower. Where a clear and sustained upward trend across several tests was recorded and simply never questioned, that can support an argument that a competent doctor should have looked harder, even if no single reading crossed the line. Whether it does depends on the records and on expert evidence.
When attributing a raised PSA to age or an enlarged prostate becomes negligence
Blaming a raised PSA on age or an enlarged prostate becomes negligence when it's done without the checks the guideline requires. Not every raised PSA that turns out to be cancer is the result of negligence, and not every decision to monitor rather than refer is wrong. An enlarged prostate (benign prostatic hyperplasia) is common and genuinely does raise PSA. The law recognises that doctors make judgement calls. The question Irish law asks is whether the judgement fell below the standard of a reasonably competent practitioner.
The standard comes from the Supreme Court's decision in Dunne v National Maternity Hospital, reaffirmed in Morrissey v HSE in 2020. A doctor is negligent only where they have done something no reasonably competent practitioner of the same standing would have done, taking ordinary care.7 Apply that here. Putting a clearly age-elevated PSA down to a benign cause is hard to defend as reasonable care, where the repeat test, the examination or the referral the guideline calls for never happened. Clinical guidelines aren't themselves binding law. The High Court reaffirmed in Perez v Coombe in 2025 that breach is judged by the Dunne test, asking what a competent professional would have done, with guidelines informing that question rather than settling it.8 But departing from a clear national guideline, with no recorded reason, is exactly the kind of gap that founds a breach.
Proving breach of duty and causation in a PSA case
A PSA claim has two parts, and both must be proven: breach and causation. The first is breach, meaning the handling of the PSA result fell below the Dunne standard. Here the man's own records do a lot of the work. The result, the date, the examination findings and whether a referral was made are all documented. Where the recorded figure sits above the age threshold and nothing followed, the gap tends to speak for itself.
In practice, a small set of records usually decides a PSA case. A solicitor will want to see:
- The laboratory PSA report itself, with the value, the date and the reference range used.
- The GP or hospital notes recording what was done with that result, and whether a digital rectal examination was carried out.
- The referral record, including any Healthlink electronic referral to a Rapid Access Prostate Clinic and its date.
- Any recall or repeat-test arrangement, which shows whether a borderline result was safely followed up.
These are the documents that show whether the result was acted on, ignored or mislaid, which is the heart of the claim.
The second part is causation, and it's where these cases are won or lost. It isn't enough that the cancer is real and the delay happened. The delay must have made a difference. Prostate cancer is often slow-growing, and a defendant will argue the outcome would have been the same regardless. Proving causation usually means instructing an independent urological or oncological expert. They compare the likely stage of the disease when the result was mishandled against its stage at eventual diagnosis. Where an earlier diagnosis would have meant less invasive, more curative treatment, that difference is the harm.
This pattern is not hypothetical in Ireland. In one reported case, a family settled for €525,000 after a GP failed to follow up blood tests that showed a dangerously elevated PSA, with advanced prostate cancer diagnosed about four years later. We set out that example, and how compensation is assessed, in our guide to test results that were not followed up. Settlement figures turn entirely on the individual facts and are not a guide to any other claim.
One breach pattern is worth singling out, because it catches people off guard. A PSA is often taken in hospital as part of a wider panel of blood tests, with several clinicians involved in a man's care. In that setting it can be unclear who owned the duty to act on a single raised result buried among routine bloods. The patient, hearing nothing, assumes no news is good news. The ordering clinician generally carries responsibility for following up the test they requested, but where the failure sits between a GP and a hospital team, the apportionment of fault is its own question. We deal with it in our guide to GP versus hospital delay.
Irish law also offers a route where strict causation is uncertain. In Philp v Ryan, the Supreme Court compensated a man whose prostate cancer was missed for eight months and treated as prostatitis. It did so even though it couldn't be proven on the balance of probabilities that the delay had shortened his life. Fennelly J held it was contrary to instinct and logic to deny compensation for the lost opportunity to be advised and treated earlier.5 That makes Ireland more favourable to patients than England, where Gregg v Scott largely closed the same door. The doctrine isn't fully settled here, though, and we explain the tension in detail in our guide to loss of chance in cancer claims.
One detail from Philp v Ryan worth knowing. The award was increased to €100,000 in total because the doctor had altered his clinical notes to suggest he'd advised a repeat PSA the man never received, an attempt to shift blame onto the patient.5 That figure is from a single 2004 case and is not a guide to any other claim. Damages in Ireland are assessed case by case under the Judicial Council Personal Injuries Guidelines (2021), and every outcome varies.10 If you suspect your records have been changed, don't confront the practice. Tell your solicitor, because the original notes can usually still be recovered.
What a claim may include, and the time limit
A PSA negligence claim may include both general damages and special damages. General damages compensate the pain, suffering and distress of an avoidable advanced diagnosis and harsher treatment. Special damages cover financial losses such as lost earnings and the cost of future care. General damages are assessed under the Personal Injuries Guidelines, and special damages aren't capped. We don't publish figures here, because every case turns on its own facts. How compensation is assessed is set out in our guide to cancer misdiagnosis compensation.
On process, a clinical negligence claim doesn't go through the Injuries Resolution Board (IRB), which assesses standard personal injury claims. Medical cases are exempt and proceed directly to the High Court, where a dedicated Clinical Negligence List now manages them.9 The time limit is generally two years less one day, but it runs from your date of knowledge, not the date of the original test. PSA cases often turn on this. A result filed away in one year may only come to light when advanced cancer is diagnosed years later. When the clock starts in a PSA case can be genuinely complex, and it's covered in our guide to date of knowledge and the time limit. Because a missed deadline removes the right to pursue compensation for the injury however strong the claim, it's worth taking advice early.
How we can help
We are personal injury solicitors in Dublin who handle complex cancer misdiagnosis claims, and we understand the precise NCCP and HSE processes that decide whether a raised PSA was properly acted on. If you are worried that an elevated or misread PSA result was not followed up, we can review your medical records and explain, in plain terms, whether the standard of care was met.
To arrange a free, confidential, no-obligation consultation, call 01 9036408 or use our enquiry form. There is no pressure and no cost to find out where you stand.
This information is for educational purposes only and does not constitute legal advice. Every case is different and outcomes vary. Consult a qualified solicitor for advice specific to your situation.
Common questions
Is it negligent if my GP didn't refer me after a raised PSA?
It can be. Where the recorded PSA was at or above the reference value for your age band, or your rectal examination was suspicious, the NCCP referral guideline points towards a Rapid Access Prostate Clinic referral. If none was made and no clinical reason was documented, that may fall below the standard of a reasonably competent GP. Whether it amounts to negligence depends on your full records and on whether the delay caused harm.
Why it matters: the breach is measured against a specific Irish guideline, not a vague impression of what was reasonable.
Next step: see failure to refer for urgent investigation.
Can you have prostate cancer with a normal PSA test?
Yes. Some men with prostate cancer have a PSA in the normal range. That is why the NCCP guideline requires a digital rectal examination alongside the blood test, and why a suspicious examination should lead to an urgent urology referral regardless of the PSA figure. A "normal" PSA does not, by itself, rule out a claim if other findings were ignored.
Why it matters: a normal number is often wrongly treated as the end of the matter.
Next step: a solicitor can check whether an examination was done and acted on.
My doctor said the raised PSA was probably my age or an enlarged prostate. Is that negligence?
Not automatically. An enlarged prostate genuinely raises PSA, and monitoring can be a reasonable choice. It becomes a concern where a clearly age-elevated reading was attributed to a benign cause without the repeat test, examination or referral the guideline calls for. The test is whether a reasonably competent doctor, applying the NCCP criteria, would have acted differently.
Why it matters: the issue is not the explanation given, but whether the required steps were taken.
Next step: see how the standard of care is applied in delayed cancer diagnosis claims.
Is it negligence if I was treated for prostatitis or a urinary infection and it turned out to be cancer?
It can be. Treating a man for prostatitis or a urinary infection is not negligent in itself, because those conditions are common and can fit the symptoms. The concern is where the response to treatment was not reviewed, a raised PSA was not acted on, or the symptoms persisted and no referral followed. In Philp v Ryan, prostate cancer was treated as prostatitis for eight months, and the Supreme Court compensated the resulting delay. Whether your case crosses the line depends on what the records show was checked and followed up.
Why it matters: a wrong working diagnosis becomes a problem when nothing prompts a rethink.
Next step: a solicitor can check whether your PSA and symptoms should have triggered referral.
Can I claim if my PSA was called normal but I had symptoms?
Possibly. A PSA within the age-related range does not rule out prostate cancer, and the NCCP guideline requires a digital rectal examination alongside the blood test. Where you had urinary symptoms or a suspicious examination and were reassured on the PSA number alone, with no examination or referral, that may fall below the standard of care. The strength of any claim turns on your records and on whether the delay caused harm.
Why it matters: symptoms and examination can demand action even when the number looks reassuring.
Next step: see failure to refer for urgent investigation.
How long do I have to make a PSA test negligence claim in Ireland?
Generally two years less one day, but the period runs from your date of knowledge rather than the date of the test. In PSA cases that date is often when you learned an earlier result should have been acted on, which can be years after the test itself. Because the timing is fact-specific, and because clinical negligence claims bypass the Injuries Resolution Board and go straight to the High Court, it is best to take advice as soon as you can.
Why it matters: missing the deadline removes the right to pursue compensation, whatever the merits.
Next step: see date of knowledge and the time limit.
References
- National Cancer Control Programme, National Prostate Cancer GP Referral Guideline (HSE/NCCP). healthservice.hse.ie (accessed 27 June 2026).
- Irish Cancer Society, Understanding PSA test results and Prostate cancer. cancer.ie (accessed 27 June 2026).
- Philp v Ryan [2004] IESC 105, Supreme Court (Fennelly J), 16 December 2004. Judgment via the Courts Service at courts.ie (accessed 27 June 2026).
- Donegal Live, "HSE admits incorrect communication released about Rapid Access Prostate Clinic" (University Hospital Galway), February 2026. donegallive.ie (accessed 27 June 2026).
- Dunne v National Maternity Hospital [1989] IR 91, reaffirmed in Morrissey v Health Service Executive [2020] IESC 6. Judgments via courts.ie (accessed 27 June 2026).
- Perez v Coombe Women and Infants University Hospital [2025] IEHC 396, High Court (Ms Justice Emily Egan), 8 July 2025, confirming that breach is assessed on the Dunne principles and that clinical guidelines inform but do not dictate the legal standard of care. Judgment via courts.ie (accessed 27 June 2026).
- Courts Service of Ireland, Clinical Negligence List (HC131/HC132), in operation from 28 April 2025. PIAB exemption for clinical negligence under the Personal Injuries Assessment Board Act 2003. courts.ie (accessed 27 June 2026).
- Judicial Council, Personal Injuries Guidelines (2021). judicialcouncil.ie (accessed 27 June 2026).
- National Cancer Institute, "PSA Velocity Does Not Improve Prostate Cancer Detection" (reporting Journal of the National Cancer Institute, 2011). cancer.gov (accessed 27 June 2026).
- Lynch T and Lonergan P, "Prostate cancer: An update on the latest NCCP GP referral guidelines," Irish Medical Times (reviewing the NCCP National Prostate Cancer GP Referral Guideline, including symptom-based referral and the lowering of the asymptomatic referral age from 50 to 40). imt.ie (accessed 27 June 2026).
- Naji L et al., "Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study," British Journal of General Practice (Irish Rapid Access Prostate Clinic data). bjgp.org (accessed 27 June 2026).
Gary Matthews Solicitors
Medical negligence solicitors, Dublin
We help people every day of the week (weekends and bank holidays included) that have either been injured or harmed as a result of an accident or have suffered from negligence or malpractice.
Contact us at our Dublin office to get started with your claim today
